Franklin Municipal Opportunities Trust PMO
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -6.36%
- 1 year
- -3.19%
- Open
- 9.95
- Prev close
- 9.95
- Mkt cap
- 281.14M
- Vol
- 49.11K
- Avg vol
- 106.66K
- EPS
- 0.85
- P/E
- 11.79
- Div yield
- 4.11%
More statistics
- Low
- 9.94
- High
- 10.07
- Forward P/E
- 0.00
- Beta
- 0.62
- Short ratio
- 0.60
- Inst. own
- 22.82%
- Dividend
- 0.42
- Ex-div date
- Dec 22, 2024
- 50-d avg
- 10.53
- 200-d avg
- 10.33
- 1y target
- 0.00
Discussion (1)
Sign in to join the discussion
$PTC Therapeutics(PTCT.US)$ ?????????????? Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi -- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.